Drug Profile
Research programme: nitric oxide-donating therapies for eye disorders - NicOx
Alternative Names: NCX 1021; NCX 1653; NCX 422; NCX 434Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator NicOx
- Class Antiglaucomas; Eye disorder therapies; Nitroso compounds
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diabetic macular oedema; Diabetic retinopathy; Glaucoma; Ocular hypertension
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Glaucoma in France (Ophthalmic)
- 23 Feb 2023 Discontinued - Preclinical for Ocular hypertension in France (Ophthalmic)
- 28 May 2020 No recent reports of development identified for preclinical development in Glaucoma in France (Ophthalmic)